Friday, November 19th

MORNING

08.30-10.30

BIOMOLECULAR, GENETIC AND PATHOLOGIC FEATURES OF CARDIA CANCER

08.30

The role of macrophages in solid tumors development

08.45

EGJ cancer: is there a molecular border?

09.00

Cardia cancer: is it still useful to maintain a separate classification between esophageal and gastric neoplasia?

09.15

Which is the clinical impact of CTC and circulating DNA in real clinical life? And tomorrow?

09.30

“The ecstasy and agony” of predictive biomarkers in current personalized medicine

09.45

Optimization of molecular-guided therapies in metastatic EGJ cancer

10.00

Why do I bust my balls every day on these issues? The perspective of a young oncological surgeon

11.00-13.00

ONCOLOGICAL FEATURES IN EGJ CANCER

11.00

May radiomics play a role in diagnostic, staging and re-staging of cardia cancer?

11.15

Perioperative chemotherapy or chemoradiotherapy in junctional cancer

11.30

Is microsatellite instability a criterion of choice for perioperative chemotherapy?

11.45

Immunotherapy of cardia cancer: which is the real clinical impact?

12.00

Adjuvant treatments in the era of ct-DNA

12.15

Molecular-based patient selection and treatment in cardia cancer

12.30

Drop out of fragile patient during neoadjuvant treatment: what we should do?

12.45

Pushing the borders of stage IV: do target therapies and immunotherapy really change treatment strategies?

13.00

Posters Round

13.30

Lunch

08.30-10.30

MINIMALLY INVASIVE SURGERY IN GASTRIC CANCER: CRITICAL QUESTIONS

08.30

Total gastrectomy: which reconstruction?

08.45

Do results of RCT solve the problems in advanced gastric cancer?

09.00

Any news about MI after neoadjuvant chemotherapy?

09.15

Borman IV, cT4b, paraortic N+: are they borders for MIS?

09.30

ICG: is it a technical, oncological enhancement or a business?

09.45

ERAS and MI surgery: are they synonymous?

10.00

Real life in Western countries: is there a harmony between clinical studies and daily practice?

11.00-13.00

ESOPHAGEAL EMERGENCIES

11.00

Do minimally invasive approaches have a role in the treatment of esophageal perforations?

11.15

Reconstruction techniques after esophageal caustic injuries: when and how?

11.30

The Pittsburgh score: is it a valuable tool to predict outcome in esophageal perforation?

11.45

When and how to treat foreign body ingestions

12.00

Esophageal stenting for refractory variceal bleeding

12.15

The role of stents in first line treatment of esophageal perforations

12.30

Management of giant paraesophageal hernia in emergency

12.45

The use of flap reinforcement in esophageal perforation repair: is it worthwhile and when?

13.00

Posters Round

13.30

Lunch

08.30-10.30

08.30

08.45

09.00

09.15

09.30

09.45

10.00

11.00-13.00

11.00

11.15

11.30

11.45

12.00

12.15

12.30

12.45

13.00

13.30

AFTERNOON

14.30-16.30

SURGICAL AND ENDOSCOPIC TREATMENT OF EGJ CANCER

14.30

Surgical approach to advanced Siewert 2 cancer: beyond the borders? The West side

14.45

Surgical approach to advanced Siewert 2 cancer: beyond the borders? The East side

15.00

Challenges in endoscopic treatment of cardia cancer: extension and depth

15.15

Lymphadenectomy in Siewert 2: does histology matter?

15.30

Esophago-gastro-anastomosi in MI Ivor-Lewis: what is the best choice?

15.45

Positive proximal margin after esophageal resection of cardia cancer: causes and management

16.00

Quality of life after resection of the cardias: esophagectomy, total gastrectomy and partial resections

16.15

Factors that may improve the results of surgery for cancer of the cardia

17.00-18.30

SURVEY PRESENTATION AND INTERSOCIETY MDTB ON CLINICAL CASES

17.00

Survey presentation

17.15

Case 1 | discussion MDTB

17.20

Pathologist

17.25

Radiologist

17.30

Oncologist

17.35

Surgeon

17.40

Case 2 | discussion MDTB

17.45

Pathologist

17.50

Radiologist

17.55

Oncologist

18.00

Surgeon

18.05

Toward harmonization

18.30

ESDE General Assembly

14.30-16.30

GASTRIC CANCER | POORLY COHESIVE TUMOURS

14.30

Epidemiology of PC gastric cancer: do we have reliable data?

14.45

Harmonization of pathological classifications between the East and the West

15.00

Does morphology reflect molecular pathology in PC cancers?

15.15

Current practice of tailored surgery in PC gastric and EGJ tumors

15.30

Current practice of tailored oncological treatment in PC gastric and EGJ tumors

15.45

Chemoresistance and potentially targetable molecular pathways in PC tumors

16.00

Tumor/stroma relationship in PC tumors

16.15

Yes … but … now? A pocket guide for PC management

17.00-18.30

ESSO UGI MEETING

17.00

17.15

17.20

17.25

17.30

17.35

17.40

17.45

17.50

17.55

18.00

18.05

18.30

IGCA eu chapter General Assembly

14.30-16.30

14.30

14.45

15.00

15.15

15.30

15.45

16.00

16.15

17.00-18.30

17.00

17.15

17.20

17.25

17.30

17.35

17.40

17.45

17.50

17.55

18.00

18.05

18.30